ClinicalTrials.Veeva

Menu

Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program for Cervical Cancer (Epi-START)

C

CHU de Reims

Status

Completed

Conditions

HPV Infection

Treatments

Biological: Human papillomavirus genotyping

Study type

Observational

Funder types

Other

Identifiers

NCT02809352
PJ12078

Details and patient eligibility

About

Cervical cancer is due to a persistent infection with a group of viruses known as high-risk Human Papillomaviruses (hrHPV). Viral DNA can be easily detected in a cervical sample by a procedure called 'HPV testing', which can be used as a relevant screening test. A pilot screening program called START-HPV has been set up in the Ardennes, a French administrative area localized in the North of France, with HPV testing as a primary screening test.This observational study aimed to evaluate hrHPV genotypes repartition in the population who participate in the START-HPV screening program. This study will allow a better knowledge of hrHPV infection epidemiology in a screened population.

Enrollment

348 patients

Sex

Female

Ages

31 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • to live in the Ardennes department (France)
  • affiliation to a health insurance organism
  • 31 to 65 years old

Exclusion criteria

  • current follow-up for cervical cytological abnormalities
  • history of hysterectomy
  • reimbursement for a Pap smear in the last 3 years

Trial design

348 participants in 1 patient group

women tested positive for hrHPV
Description:
All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
Treatment:
Biological: Human papillomavirus genotyping

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems